Drug Trial Radar · NCT04589403
1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Feb 18, 2021
Primary completion
Sep 27, 2021
Study completion Sep 27, 2021
Sponsor
- Lead sponsor
- Op-T LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.
Conditions
- Healthy
Interventions
OPT101Drug
15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Time frame: 21 days
- Rate and type of adverse events during and after infusion of OPT101 or placeboTime frame: 48 hours
- Incidence of vital signsTime frame: 48 hours
- Incidence of abnormal laboratory valuesTime frame: 21 days
- Definition of maximum tolerated (MTD) single and repeated doses of OPT101Time frame: 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IMMUNOe Research
Centennial, Colorado
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.